title: Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly Tumors.
abstract: Uterine sarcomas are rare malignant uterine neoplasms that are responsible for a large majority of uterine cancer-associated deaths. The subtypes include leiomyosarcomas, endometrial stromal tumors, and adenosarcomas. Standard treatment includes complete surgical resection. Adjuvant treatment with chemotherapy, hormonal therapy, or radiation may be considered in patients with high-risk disease. However, because the ability of adjuvant treatment to improve overall survival in patients with uterine sarcomas is unclear, there is no standard recommendation regarding adjuvant therapy. The risk in forgoing chemotherapy is that uterine sarcomas have a tendency to develop distant recurrences. Many cytotoxic agents have been investigated in clinical trials in an attempt to identify an effective treatment that can improve the course of this disease. Adjuvant radiation appears to improve local control but has no significant impact on survival. In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas.
authors.forename: Jing-Yi
authors.initials: JY
authors.lastname: Chern
authors.forename: Leslie R
authors.initials: LR
authors.lastname: Boyd
authors.forename: Stephanie V
authors.initials: SV
authors.lastname: Blank
mesh_terms: D017024:Chemotherapy, Adjuvant / Q000639:trends; D018450:Disease Progression; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects / Q000639:trends*; D008495:Medical Oncology / Q000639:trends*; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant / Q000639:trends; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*